GAGomes as early detection biomarkers: multi-cancer
Recent evidence suggests that metabolic reprogramming of GAGomes is an ubiquitous process in cancers. In a clinical study with over...
Subsequent studies highlighted a suggestive correlation between the extent to which the GAGome deviates from normal healthy levels and the severity of cancer (Gatto et al., 2016).
Progression-free survival in metastatic patients split into two groups depending on the urine GAGome-base score. Adapted from Gatto et al. 2016.
Elypta is currently exploring the use of GAGomes for the prognosis of muscle-invasive bladder cancer before neo-adjuvant chemotherapy in AURORAX-0093A, a VINNOVA co-funded study.
